After finishing at $50.71 in the prior trading day, Celldex Therapeutics Inc. (NASDAQ: CLDX) closed at $50.01, down -1.38%. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 2259078 shares were traded.
Ratios:
Our goal is to gain a better understanding of CLDX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.87 and its Current Ratio is at 13.87. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 10, 2023, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $27.
On August 22, 2023, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $21.Wells Fargo initiated its Underweight rating on August 22, 2023, with a $21 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 2.80B and an Enterprise Value of 2.37B. For the stock, the TTM Price-to-Sale (P/S) ratio is 406.33 while its Price-to-Book (P/B) ratio in mrq is 6.51. Its current Enterprise Value per Revenue stands at 344.99 whereas that against EBITDA is -17.08.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.11. The 50-Day Moving Average of the stock is 39.83, while the 200-Day Moving Average is calculated to be 33.04.
Shares Statistics:
The stock has traded on average 826.37K shares per day over the past 3-months and 1.69M shares per day over the last 10 days, according to various share statistics. A total of 55.88M shares are outstanding, with a floating share count of 54.32M. Insiders hold about 2.83% of the company’s shares, while institutions hold 108.45% stake in the company. Shares short for CLDX as of Feb 15, 2024 were 6.94M with a Short Ratio of 8.40, compared to 6.22M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.42% and a Short% of Float of 14.60%.
Earnings Estimates
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of -$0.73 for the current quarter, with a high estimate of -$0.65 and a low estimate of -$0.89, while EPS last year was -$0.62. The consensus estimate for the next quarter is -$0.75, with high estimates of -$0.67 and low estimates of -$0.89.
Analysts are recommending an EPS of between -$2.75 and -$3.58 for the fiscal current year, implying an average EPS of -$3.12. EPS for the following year is -$3.21, with 6 analysts recommending between -$1.76 and -$4.03.
